We report a refined procedure of the ferric chloride (FeCl3)-induced thrombosis models on carotid and mesenteric artery as well as vein, characterized efficiently using intravital microscopy to monitor time to occlusive thrombi formation.
Arterial thrombosis (blood clot) is a common complication of many systemic diseases associated with chronic inflammation, including atherosclerosis, diabetes, obesity, cancer and chronic autoimmune rheumatologic disorders. Thrombi are the cause of most heart attacks, strokes and extremity loss, making thrombosis an extremely important public health problem. Since these thrombi stem from inappropriate platelet activation and subsequent coagulation, targeting these systems therapeutically has important clinical significance for developing safer treatments. Due to the complexities of the hemostatic system, in vitro experiments cannot replicate the blood-to-vessel wall interactions; therefore, in vivo studies are critical to understand pathological mechanisms of thrombus formation. To this end, various thrombosis models have been developed in mice. Among them, ferric chloride (FeCl3) induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. This model is based on redox-induced endothelial cell injury, which is simple and sensitive to both anticoagulant and anti-platelets drugs. The time required for the development of a thrombus that occludes blood flow gives a quantitative measure of vascular injury, platelet activation and aggregation that is relevant to thrombotic diseases. We have significantly refined this FeCl3-induced vascular thrombosis model, which makes the data highly reproducible with minimal variation. Here we describe the model and present representative data from several experimental set-ups that demonstrate the utility of this model in thrombosis research.
Arterial thrombosis (blood clot) is a common complication of many systemic diseases associated with chronic inflammation, including atherosclerosis, diabetes, obesity, cancer and chronic autoimmune rheumatologic disorders. Thrombi that occur in the arterial circulation stem from inappropriate platelet activation, aggregation and subsequent coagulatory mechanisms, and are implicated in heart attacks, strokes and extremity loss. The vessel wall is a complex system that includes multiple cell types and is influenced by a multitude of extrinsic factors including shear stress, circulating blood cells, hormones and cytokines, as well as expression of antioxidant proteins in the vessel wall. In vitro experiments cannot replicate this complex environment and therefore in vivo studies using animal models are critical to allow better understanding of mechanisms involved in thrombotic disorders.
Mice have been shown to have similar mechanisms to humans in terms of thrombosis, atherosclerosis, inflammation and diabetes1,2. Furthermore, transgenic and knockout mice can be created to test the function of specific gene products in a complex physiologic or pathologic environment. Such studies mimic human pathology and may provide important mechanistic information related to discovery of new pathways and therapies, as well as provide important details in characterizing drug effects on thrombosis.
Pathological arterial thrombi occur due to endothelial layer injury or dysfunction and exposure of the blood stream to the subendothelial matrix3,4. Various thrombosis models have been developed to induce this endothelial damage such as mechanical injury, photoreactive compound Rose Bengal-based oxidative injury and laser injury5. In this spectrum, Ferric chloride (FeCl3)-induced vascular injury is a widely used model of thrombosis. This reagent when applied to the outer aspect of vessels induces oxidative damage to vascular cells6-8, with loss of endothelial cell protection from circulating platelets and components of the coagulation cascade. The FeCl3 model is simple and sensitive to both anticoagulant and anti-platelets drugs, and has been performed on carotid and femoral arteries, jugular veins, and mesenteric and cremasteric arterioles and venules in mice, rats, guinea pigs and rabbits6-15.
One measurable parameter in this model is the elapsed time from injury to complete vessel occlusion, measured as blood flow cessation with a Doppler flow meter or under direct observation with intravital microscopy6,7,9. A range of times between 5 to 30 min has been reported in different studies in C57Bl6 mice7-10,16, suggesting that FeCl3 concentrations, types of anesthesia, surgical techniques, mouse age, genomic background, method of measuring blood flow, and other environmental variables have significant effects in this model. This wide variability makes it difficult to compare studies from different research groups and may make detection of subtle differences difficult.
With a vision to minimize such variabilities and establish a uniformly reproducible in vivo model system, we have refined the FeCl3-induced carotid artery model that makes the data highly reproducible with minimal variation6-10,16-19. In this paper we describe and share the skills and report several representative experimental examples that can benefit from this model.
All procedures and manipulations of animals have been approved by Institutional Animal Care and Use Committees (IACUC) of The Cleveland Clinic in accordance with the United States Public Health Service Policy on the Humane Care and Use of Animals, and the NIH Guide for the Care and Use of Laboratory Animals.
1. Preparations:
2. FeCl3 Induced Carotid Arterial Injury Thrombosis Model
3. FeCl3 Induced Mesenteric Artery/Vein Thrombosis Model
Carotid Artery Thrombosis Model
In mice with C57BL6 background, we recommend using 7.5% FeCl3 to treat the vessel for 1 min as a starting point. Under treatment of 7.5% FeCl3, borders of the injured area and normal vessel wall are easily identified under microscope (See online video 1), suggesting that the endothelial layer was significantly damaged. The thrombi formed immediately upon FeCl3 treatment, and are observed in all WT C57BL6 mice 1 min after injury. The initially formed thrombi are unstable and parts of them are usually washed away by the blood stream, so the formed thrombi become smaller at 2 – 3 min after injury. Thrombi start to enlarge from 3 – 4 min after removing the filter paper and these later formed thrombi are stable and usually are not washed away. The average occlusive time is 11.3 ± 3.16 min in the C57BL6 mice (n= 14) when 7.5% FeCl3 is used6,7,19 (Figure 5A and online video 1). In the previous studies we have demonstrated that both decrease and increase of FeCl3 concentrations diminish the difference between an anti-thrombotic mouse strain and WT mice6; From our experience, treatment of the carotid artery with 7.5% FeCl3 for 1 min is sufficient to satisfy all of our purposes. In addition to test function of specific genes using knockout mice7,8,16,19,21, following are four representative experiments using this model:
Intravenous Perfusion of tissue-type Plasminogen Activator Mediated Thrombolysis
Tissue-type plasminogen activator (tPA) is one of the FDA-approved drugs for thrombolysis treatment in the United States22. We thus observed the tPA-mediated thrombolysis in the carotid artery thrombosis model. Thrombosis was initiated with 7.5% FeCl3 and allowed to form for 5 min before tPA (1 mg/Kg body weight) was perfused via a jugular vein catheter (22GA). As shown in Figure 5B and online video 2, the thrombus continually magnified and occupied about 50% of the lumen 5 min after injury. The thrombi continued to enlarge after tPA perfusion suggesting that tPA does not affect platelet activation and aggregation. Thrombolysis started about 4 minutes after tPA injection. The formed thrombi were found to undergo size variations repeatedly during the 30 min observation period and no vessel occlusion happened in this case. These data clearly showed that tPA cannot completely inhibit platelet-mediated thrombus formation, even if it leads to thrombolysis. Therefore, we envision that future experiments utilizing the FeCl3-induced arterial thrombosis model can be utilized to evaluate thrombolytic and other adjunctive therapies that can have a prominent preventative effect on thrombus formation.
Perfusion of PAR4 Antibody to Mice Inhibits Thrombosis
Protease activated receptor 4 (PAR4) is a G protein coupled receptor (GPCR) on platelets which is activated by proteolytic cleavage of its N-terminal exodomain23 and subsequently leads to steps in platelet activation. The Nieman lab has generated a goat polyclonal PAR4 antibody (CAN12) that targets the anionic cluster of PAR4, and delays PAR4 cleavage, thereby affecting a critical step for PAR4 mediated platelet activation24. By perfusion of 1 mg/Kg of this antibody to the C57BL6 mice, we found that inhibition of PAR4 cleavage significantly prolonged times to occlusive thrombus formation in the 7.5% FeCl3 induced carotid artery thrombosis model (Figure 5C and online video 3). This demonstrates that the FeCl3-induced thrombosis model can be utilized to evaluate the effects of anti-platelet agents and characterize potential therapeutic strategies.
Nanoparticle-mediated Thrombi-specific Targeting
Rapid clot-removal to re-establish blood flow is crucial in treating occlusive vascular diseases including ischemic stroke and myocardial infarction. Systemic delivery of thrombolytic drugs, such as tPA showed above, can lyse the formed thrombi, but cannot completely prevent platelet activation and re-aggregation/occlusion. Additionally, systemic direct delivery of such serine protease agents can lead to indiscriminate off-target action, leading to major side effects including hemorrhage. The Sen Gupta lab has engineered platelet-inspired nanoparticle-based synthetic delivery vehicles that can bind to clot-associated activated platelets and proteins under hemodynamic shear flow25-27. We thus examined whether these nanoparticles can bind to the actively forming thrombi in an artery.
As mentioned in experiment for tPA perfusion, a catheter was inserted into the jugular vein and connected to an Injection Pump for injection of nanoparticle at uniform flow rate. In this experiment, no fluorescence dye was injected into the mouse to label platelets. Instead, the nanoparticles were labeled with Rohdamine B; therefore they were able to be observed under intravital microscope. The thrombosis was initiated with 7.5% FeCl3 treatment for 1 min as mentioned previously. Since in WT mice, a significant amount of thrombi was found to form 5 min after injury, we selected this time point for injection of nanoparticles to detect if the nanoparticles bind efficiently to the actively forming thrombi. As shown in Figure 5D and online video 4, after injection of fluorescent nanoparticles, we were able to identify a mountain-shaped thrombus which got progressively covered by the fluorescent particles. These studies demonstrate the utility of the FeCl3-induced thrombosis model to evaluate the targeting capability (and subsequent therapeutic efficacy) of clot-targeted particulate drug delivery systems.
Role of Red Blood Cells other than Platelets in Thrombus Formation.
Recent studies have suggested that red blood cells (RBCs) play important role in the FeCl3 induced thrombosis model28 and they are the first adherent blood component to the injured vessel wall29,30. To explore this phenomenon, we labeled RBCs with 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (Dil, 10 µM final concentration). The Dil-labeled RBCs were washed two times with PBS and resuspended in saline with 35% hematocrit. The Dil-labeled RBC suspension (100 µl per mouse) was injected into the thrombocytopenic mice which have been lethally irradiated 5 days before the experiment19. These thrombocytopenic mice have significant decreased platelets, which will increase the chance of RBC biding to the vessel wall, if they do. In contrast to the experiments using fluorescence-labeled platelets (Figure 5), no obvious accumulation of fluorescent cells was found on the vessel wall after vascular injury (Figure 6A, online video 5). However, along with the formation of the platelet-rich thrombi, RBCs started to accumulate in the thrombus which illustrates the shape of the clot (Figure 6A). Immunofluorescence staining of the injured carotid artery demonstrated that the major cells adhered to the vessel wall are platelets (CD41 positive, green), while the Dil-labeled RBCs are mainly trapped within the thrombi (Figure 6B & C). These studies demonstrate that the FeCl3-induced thrombosis model can be utilized in gaining mechanistic insight on cellular and molecular components and spatio-temporal events in thrombus formation.
Mesenteric Thrombosis Model
For the mesenteric thrombosis model, a high concentration of FeCl3 (10 – 12.5%) is recommended as the vessels are usually surrounded by fat tissue, which can hinder the FeCl3 diffusion towards the vessel wall and thus prevents vessel from FeCl3-induced injury7. This model is more suitable for venous thrombosis study. As shown in online video 6, thrombus was seen around ~15 sec in the mesenteric vein after topically applying the filter paper saturated with 12.5% FeCl3 solution, but thrombus formation is dramatically delayed in the mesenteric artery. The average time to occlusive thrombus formation is ~17 ± 7.2 min (n = 11) in mesenteric vein and about 23 ± 9.9 min (n = 10) in mesenteric artery when 12.5% FeCl3 is used7.
Figure 1. Surgery Tools. The minimal necessary tools for mouse surgery are shown. See Materials list for more detailed information. Please click here to view a larger version of this figure.
Figure 2. Mouse Fixation for Surgery. Secure the mouse on the 15 cm culture dish lid for carotid artery thrombosis model or for the injection of rhodamine 6G dye for the mesenteric thrombosis model. Please click here to view a larger version of this figure.
Figure 3. Carotid Artery Thrombosis Model. Procedures to expose the jugular vein, injection of rhodamine 6G florescent dye into the blood system and exposure of left carotid artery are shown. In (A), the line indicates the incision from manubrium to the level of the hyoid bone; in (B), blue arrows indicate submaxillary glands, and yellow dotted lines represent the fascia between the submaxillary glands; in (C), blue arrows indicate submaxillary glands, black arrow indicates manubrium, and dotted yellow line indicates the position to cut to expose the jugular vein; in (D), blue arrow indicates jugular vein; in (E), yellow arrow indicates left submaxillary gland, blue arrow indicates left sternocleidomastoid muscle, dotted yellow line indicates fascia, and green arrow indicates the omohyoid muscle or the sternohyoid muscle; in (F), blue arrow indicates carotid artery, the yellow dotted lines show the thin sternohyoid muscle and/or the omohyoid muscle; in (G), the blue arrow indicates carotid artery and green arrow indicates vagus nerve; in (H), the blue arrow indicates carotid artery and the green arrow indicates the plastic "U-shape" coffee stirrer; and in (I), the blue arrow indicates the filter paper situated with FeCl3 solution, and green arrow indicates the carotid artery. T indicates trachea. Please click here to view a larger version of this figure.
Figure 4. Mesenteric Artery and Vein Thrombosis Model. Exposure of mesenteric vessels as well as FeCl3 treatment is shown. In (A), the blue arrow indicates linea alba, the white fibrous tissue without vessel; In (B), an incision cut alone the linea alba was shown; in (C), the blue arrows indicate the second arch of the mesenteric arteries and veins; in (D), the blue arrow indicates the filter paper situated with FeCl3 solution. Please click here to view a larger version of this figure.
Figure 5. Representative Experiments using the Carotid Artery Thrombosis Model. (A). Thrombus formation in theC57Bl/6 mouse treated with 7.5% FeCl3. (B). tPA mediated thrombolytic effect. (C). Injection of antibody targeting mouse thrombin receptor PAR4 on thrombosis was shown. (D). Thrombus-site-targeted nanovehicles specifically bind to actively forming thrombi was shown. Inj. P indicates injection of particle; and Peak B indicates peak banding of particles to the thrombi. All images were taken under same magnification. Scale bar = 300 µm. Please click here to view a larger version of this figure.
Figure 6. Role of RBC on Thrombus Formation. (A) Thrombocytopenic mice that received perfusion of Dil-labeled RBCs were subjected to the carotid artery thrombosis model and images after 7.5% FeCl3 treatment were shown. Bar = 300 µm. (B & C) The injured carotid arteries were harvested, and frozen sections were prepared. Platelets were stained with CD41 (Green) and RBCs were shown as red (Dil). Nuclei were stained with DAPI. Vessels shown in (B and C) were from two different mice. Scale bars = 50 µm. Please click here to view a larger version of this figure.
Video 1: Representative video of the carotid artery thrombosis model in wild type (WT) mice. (Right-click to download.) This video shows the representative thrombus formation in the carotid artery of WT mice induced by topically applying filter paper situated with 7.5% FeCl3 solution. Platelets were labelled by intravenous injection of rhodamine 6G, and video was taken in monochrome mode. The white mass is clotted platelets.
Video 2: Tissue plasminogen activator (tPA) mediated thrombolytic effect detected by the carotid artery thrombosis model. (Right-click to download.) Platelet labelling and thrombus formation were initiated as mentioned in video 1, and tPA was injected intravenously 5 min after 7.5% FeCl3 injury.
Video 3: Antiplatelet drug, namely anti-protease activated receptor 4 (PAR4) antibody, mediated anti-thrombotic effect detected by the carotid artery thrombosis model. (Right-click to download.) In this experiment, mice received PAR4 antibody and rhodamine 6G injection 10 min before thrombus formation was initiated by topically applying filter paper situated with 7.5% FeCl3.
Video 4: Nanoparticle-mediated thrombi-specific targeting. (Right-click to download.) In this experiment, carotid artery thrombus formation was initiated with 7.5% FeCl3 without labeling platelet. Nanoparticle was labeled with Rhodamine B and intravenously injected into the mouse 5 min after injury.
Video 5: Binding of the red blood cells detected by the carotid artery thrombosis model. (Right-click to download.) Red blood cells (RBCs) were labelled with 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (Dil, 10 µM final concentration), and 100 µl of the Dil-labeled RBCs (35% hematocrit) were injected into the thrombocytopenic mice. No platelet labeling was performed in this experiment. Thrombus was initiated as mentioned above with7.5% FeCl3.
Video 6: Representative video of the mesenteric artery and vein thrombosis model on WT mice. (Right-click to download.) Platelets were labelled by intravenous injection of rhodamine 6G, and thrombus was initiated topically after applying one piece of filter paper with 12.5% FeCl3 solution for 1 min. The vessel was observed under 10X dry lens.
The FeCl3-induced model is one of the most widely used thrombosis models, which can not only provide valuable information about genetic modifications on platelet function and thrombosis7,8,16,19,31-33, but can also be a valuable tool for evaluation of therapeutic compounds and strategies for treatment and prevention of atherothrombotic diseases11,17,34-37. Here we have shown our modifications and refinements of this model and showed additional evidence of the utility of this technique, which is sufficiently sensitive to determine the effects of anticoagulant (tPA) and anti-platelet drugs (PAR4 antibody). In addition to the mechanistic study of thrombosis, the model can also be utilized to study nanotechnologies-based, thrombi-targeted drug delivery. It can also be used for detection of vessel wall reactive oxygen species (ROS) formation by injection of fluorescent ROS indicator21.
Meticulous techniques are necessary to perform these models. The operator should have sufficient surgical skills as well as a deep understanding of vascular and blood cell biology. Several key points of the FeCl3 induced carotid artery thrombosis model are6: (1) expose enough length of carotid artery (~5 mm) to allow application of the filter paper and leave a space to observe blood flow under intravital microscopy at late phase; (2) clearly strip the adventitial soft tissue around the carotid artery to allow the filter paper to contact the vessel wall directly and produce an even injury; (3) confirm no mechanical injury to the vessel wall and no thrombus formation before application of FeCl3-saturated filter paper; (4) underlie the carotid artery with a piece of "U" shaped black plastic to separate the artery from surrounding tissue, to block background fluorescence, and to prevent FeCl3 diffusion. By these strategies, we have generated highly reproducible data with the wild type C57Bl/6 mice, and in this mouse strain 7.5% FeCl3 induced thrombosis time is 11.3 ± 3.16 min (n= 14)6,7,19. The jugular vein injection of rhodamine 6G to label circulating cells may be challenging. As an alternative, a tail vein injection can be performed before securing the mouse on the 15 cm plate lid. In comparing to the carotid artery model, the mesenteric artery and vein model is easier and less surgically intensive. However, as mentioned in the Result Section, due to the coverage of the vessels by fat tissue, the mesenteric thrombosis model is better for studying venous thrombosis but requires a larger sample size to minimize the error between different mice.
The limitation of this model is that the mechanism is not clear and still controversial. Initially, the mechanism of this model was believed to be that of FeCl3 generated ROS induced denudation of endothelial cells, and subsequently led to exposure of blood components to the prothrombotic subendothelium, to render platelet adhesion, aggregation and thrombus formation6,11. By reconstitution of platelets pre-treated with GPVI antibody to the thrombocytopenic mice, we have demonstrated that the FeCl3 model depends on platelet GPVI, and blocking platelet GPVI dramatically inhibited FeCl3 induced thrombi formation19. This finding is in line with previous reports38 and suggests that the FeCl3 model may be more likely to mimic the pathophysiology of human atherosclerotic plaque rupture mediated thrombosis6. However, several recent studies have proposed new mechanisms including adhesion of red blood cells to the vessel wall as well as physiochemical effect of FeCl3 induced aggregation of plasma proteins and blood cells29,30. These new insights suggest the potential mechanisms of this model may be more complex.
By perfusion of Dil-labeled RBCs into the thrombocytopenic mice and then inducing FeCl3-triggered injury to the carotid artery with 7.5% FeCl3, we found that the major cells adhering to the injured vessel walls are platelets (Figure 6 and online video 5). We did not find obvious RBCs adhesion, and the accumulation of RBCs in the thrombi seemed most likely to be a result of trapping. Our findings match the concepts of primary and secondary hemostasis39. The difference of our observation from the previous reports may be from hypoxia and hemodynamic change as in the study by Barr and colleagues30, where the FeCl3 injured carotid arteries for scanning electron microscopy examination were prepared in mice that had the left ventricle previously exposed without assistance of a mechanical ventillation. Blood oxygen concentration and hemodynamics will be dramatically decreased as both pulmonary and cardiac function will be affected immediately after the chest is opened without mechanical ventilation. Oxygen deprivation has long been associated with triggering of the procoagulant pathway and thrombosis40 and also may enhance RBC adhesion. Another recent publication has shown that treatment of the carotid artery with a very high concentration of FeCl3 (20%) for 5 or 10 min leads to a steady-state concentration of FeCl3 at ~ 50 mM in the lumen of the injured vessel29. They thus directly infused 50 mM FeCl3 into various blood components and examined the effect of FeCl3 on aggregation ex vivo, which led them to propose a novel, 2-phase mechanism for the action of FeCl3 in thrombus formation29. Although quite interesting, results from this study need to be interpreted with caution as it does not represent the FeCl3 model commonly used. In contrast to the high concentration of FeCl3 (20%, 1M as indicated in the paper) and long treatment (5 or 10 min), our previous studies as well as Barr et al. have demonstrated that 10% FeCl3 treatment for 1 min is enough to induce rapid occlusive thrombus formation in the carotid artery within 7 min6,30. In addition, in most of the experiments using the FeCl3 model, a further low concentration of FeCl3 (5 – 7.5%) is used.
Another limitation of this model is that due to the severe oxidative injury to the endothelium as well as endothelial denudation post-FeCl3 treatment, this model may be not a proper tool to study endothelial inflammation associated thrombosis. However, by using these techniques to prepare the carotid artery in combination with perfusion of fluorescently labeled leukocytes, we can test the adhesion and rolling of the leukocytes on the inflammatory endothelium41.
In summary, we have refined and standardized the FeCl3-induced vascular injury model to produce a highly reproducible injury on the carotid artery and quantitate blood flow cessation time accurately by intravital microscopy. This model is sufficient and sensitive to test the anticoagulant and antiplatelet drugs, and is also suitable for studies of thrombi-targeted nanomedicine. In combination with bone marrow transplantation, platelet infusion into the thrombocytopenic mice or direct intravascular injection of candidate drugs, we have demonstrated that this is a convenient, simple and sensitive tool to study thrombosis in vivo7-10,16,19,42,43.
The authors have nothing to disclose.
This work was supported by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health under award numbers R01 HL121212 (PI: Sen Gupta), R01 HL129179 (PI: Sen Gupta, Co-I: Li) and R01 HL098217 (PI: Nieman). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Surgical Scissors – Tungsten Carbide | Fine Science Tools | 14502-14 | cut and hold skin |
Micro-Adson Forceps – Serrated/Straight/12cm | Fine Science Tools | 11018-12 | cut and hold skin |
Metzenbaum Fino Scissors – Tungsten Carbide/Curved/Blunt-Blunt/14.5cm | Fine Science Tools | 14519-14 | to dissect and separate soft tissue |
Ultra Fine Hemostat – Smooth/Curved/12.5cm | Fine Science Tools | 13021-12 | to dissect and separate soft tissue |
Graefe Forceps – Serrated/Straight/10cm | Fine Science Tools | 11050-10 | to dissect and separate soft tissue |
Dumont #5 Fine Forceps – Biology Tips/Straight/Inox/11cm | Fine Science Tools | 11254-20 | Isolate vessel from surounding tissue |
Dumont #5XL Forceps – Standard Tips/Straight/Inox/15cm | Fine Science Tools | 11253-10 | Isolate vessel from surounding tissue |
Blunt Hook- 12cm/0.3mm Tip Diameter | Fine Science Tools | 10062-12 | Isolate vessel from surounding tissue |
Castroviejo Micro Needle Holders | Fine Science Tools | 12061-02 | Needle holders |
Suture Thread 4-0 | Fine Science Tools | 18020-40 | For fix the incisors to the plate |
Suture Thread 6-0 | Fine Science Tools | 18020-60 | For all surgery and ligation |
Kalt Suture Needles | Fine Science Tools | 12050-03 | |
rhodamine 6G | Sigma | 83697-1G | To lebel platelets |
FeCl3 (Anhydrous) | Sigma | 12321 | To induce vessel injury |
Papaverine hydrochloride | Sigma | P3510 | To inhibit gut peristalsis. |
Medline Surgical Instrument Sterilization Steam Autoclave Tapes | Medline | 111625 | To fix the mouse to the plate |
Fisherbrand™ Syringe Filters – Sterile 0.22µm | Fisher | 09-720-004 | For sterlization of solutions injected to mice |
Fisherbrand™ Syringe Filters – Sterile 0.45µm | Fisher | 09-719D | To filter the FeCl3 solution |
Sterile Alcohol Prep Pad | Fisher | 06-669-62 | To sterilize the surgical site |
Agarose | BioExpress | E-3120-500 | To make gel stage |
Leica DMLFS fluorescent microscope | Leica | Intravital microscope | |
GIBRALTAR Platform and X-Y Stage System | npi electronic GmbH | http://www.npielectronic.de/products/micropositioners/burleigh/gibraltar.html | |
Streampix version 3.17.2 software | NorPix | https://www.norpix.com/ |